{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:48:47Z","timestamp":1787662127659,"version":"build-2736575974"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T00:00:00Z","timestamp":1532044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015693","name":"Purdue Pharma","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015693","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40258-018-0402-x","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T02:05:11Z","timestamp":1532052311000},"page":"609-632","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017"],"prefix":"10.1007","volume":"16","author":[{"given":"Marcia","family":"Reinhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Scarpati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noam Y.","family":"Kirson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer G.","family":"Erensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,20]]},"reference":[{"key":"402_CR1","unstructured":"Ahrnsbrak R, Bose J, Hedden SL, Lipari RN, Park-Lee E. Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health. 2017. \n                    https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR1-2016\/NSDUH-FFR1-2016.htm#opioid1\n                    \n                  . Accessed 23 Jan 2018."},{"issue":"8","key":"402_CR2","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/add.12551","volume":"109","author":"L Degenhardt","year":"2014","unstructured":"Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320\u201333. \n                    https:\/\/doi.org\/10.1111\/add.12551\n                    \n                  .","journal-title":"Addiction."},{"key":"402_CR3","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.","edition":"5"},{"key":"402_CR4","unstructured":"Hedegaard H, Warner M, Mini\u00f1o AM. Drug overdose deaths in the United States, 1999\u20132016. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2017. Report No.: 294."},{"key":"402_CR5","unstructured":"Hughes A, Williams MR, Lipari RN, Bose J, Copello EAP, Kroutil LA. Prescription drug use and misuse in the United States: results from the 2015 National Survey on Drug Use and Health. In: NSDUH Data Review. 2016. \n                    https:\/\/www.samhsa.gov\/data\/sites\/default\/files\/NSDUH-FFR2-2015\/NSDUH-FFR2-2015.htm\n                    \n                  . Accessed 02 Jan 2018."},{"key":"402_CR6","unstructured":"National Institutes of Health. What is the federal government doing to combat the opioid abuse epidemic? Testimony by Nora D. Volkow, Director, National Institute on Drug Abuse House Committee on Energy and Commerce, Subcommittee on Oversight and Investigations. 2015. \n                    https:\/\/www.drugabuse.gov\/about-nida\/legislative-activities\/testimony-to-congress\/2016\/what-federal-government-doing-to-combat-opioid-abuse-epidemic\n                    \n                  . Accessed 02 Jan 2018."},{"key":"402_CR7","unstructured":"National Institutes of Health. Federal efforts to combat the opioid crisis: a status update on CARA and other initiatives. Testimony by Nora Volkow, Director, National Institute on Drug Abuse and others to House Committee on Energy and Commerce. 2017. \n                    https:\/\/www.drugabuse.gov\/about-nida\/legislative-activities\/testimony-to-congress\/2017\/federal-efforts-to-combat-opioid-crisis-status-update-cara-other-initiatives\n                    \n                  . Accessed 02 Jan 2018."},{"issue":"4","key":"402_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/j.1526-4637.2011.01075.x","volume":"12","author":"HG Birnbaum","year":"2011","unstructured":"Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med. 2011;12(4):657\u201367. \n                    https:\/\/doi.org\/10.1111\/j.1526-4637.2011.01075.x\n                    \n                  .","journal-title":"Pain Med."},{"issue":"6","key":"402_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1089\/pop.2013.0098","volume":"17","author":"R Meyer","year":"2014","unstructured":"Meyer R, Patel AM, Rattana SK, Quock TP, Mody SH. Prescription opioid abuse: a literature review of the clinical and economic burden in the United States. Popul Health Manag. 2014;17(6):372\u201387. \n                    https:\/\/doi.org\/10.1089\/pop.2013.0098\n                    \n                  .","journal-title":"Popul Health Manag."},{"issue":"4","key":"402_CR10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/15360288.2015.1101641","volume":"29","author":"GM Oderda","year":"2015","unstructured":"Oderda GM, Lake J, Rudell K, Roland CL, Masters ET. Economic burden of prescription opioid misuse and abuse: a systematic review. J Pain Palliat Care Pharmacother. 2015;29(4):388\u2013400. \n                    https:\/\/doi.org\/10.3109\/15360288.2015.1101641\n                    \n                  .","journal-title":"J Pain Palliat Care Pharmacother."},{"issue":"7","key":"402_CR11","doi-asserted-by":"publisher","first-page":"556","DOI":"10.18553\/jmcp.2009.15.7.556","volume":"15","author":"SA Strassels","year":"2009","unstructured":"Strassels SA. Economic burden of prescription opioid misuse and abuse. J Manag Care Spec Pharm. 2009;15(7):556\u201362. \n                    https:\/\/doi.org\/10.18553\/jmcp.2009.15.7.556\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"4","key":"402_CR12","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65\u201394.","journal-title":"Ann Intern Med."},{"issue":"4","key":"402_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151(4):264\u20139 (W64).","journal-title":"Ann Intern Med."},{"issue":"2","key":"402_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jval.2013.12.011","volume":"17","author":"ML Berger","year":"2014","unstructured":"Berger ML, Martin BC, Husereau D, Worley K, Allen D, Yang W, et al. A questionnaire to assess the relevance and credibility of observational studies to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. Value Health. 2014;17(2):143\u201356. \n                    https:\/\/doi.org\/10.1016\/j.jval.2013.12.011\n                    \n                  .","journal-title":"Value Health."},{"issue":"2","key":"402_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1046\/j.1524-4733.2003.00242.x","volume":"6","author":"B Motheral","year":"2003","unstructured":"Motheral B, Brooks J, Clark MA, Crown WH, Davey P, Hutchins D, et al. A checklist for retrospective database studies\u2013report of the ISPOR Task Force on Retrospective Databases. Value Health. 2003;6(2):90\u20137. \n                    https:\/\/doi.org\/10.1046\/j.1524-4733.2003.00242.x\n                    \n                  .","journal-title":"Value Health."},{"issue":"7052","key":"402_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ (Clinical Research ed). 1996;313(7052):275\u201383.","journal-title":"BMJ (Clinical Research ed)."},{"issue":"10-a Suppl","key":"402_CR17","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.18553\/jmcp.2016.22.10-a.s1","volume":"22","author":"J Howard","year":"2016","unstructured":"Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, et al. Diagnosis-level drivers and trajectory of excess costs prior to and after diagnosis of opioid abuse. J Manag Care Spec Pharm. 2016;22(10-a Suppl):S44. \n                    https:\/\/doi.org\/10.18553\/jmcp.2016.22.10-a.s1\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"4","key":"402_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.18553\/jmcp.2017.16265","volume":"23","author":"NY Kirson","year":"2017","unstructured":"Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ. The economic burden of opioid abuse: Updated findings. J Manag Care Spec Pharm. 2017;23(4):427\u201345. \n                    https:\/\/doi.org\/10.18553\/jmcp.2017.16265\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"4","key":"402_CR19","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40258-014-0102-0","volume":"12","author":"JB Rice","year":"2014","unstructured":"Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, et al. Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data. Appl Health Econ Health Policy. 2014;12(4):435\u201346. \n                    https:\/\/doi.org\/10.1007\/s40258-014-0102-0\n                    \n                  .","journal-title":"Appl Health Econ Health Policy."},{"issue":"4","key":"402_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3810\/pgm.2014.07.2783","volume":"126","author":"JB Rice","year":"2014","unstructured":"Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, et al. The economic burden of diagnosed opioid abuse among commercially insured individuals. Postgrad Med. 2014;126(4):53\u20138. \n                    https:\/\/doi.org\/10.3810\/pgm.2014.07.2783\n                    \n                  .","journal-title":"Postgrad Med."},{"issue":"5","key":"402_CR21","first-page":"276","volume":"23","author":"LM Scarpati","year":"2017","unstructured":"Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC. Drivers of excess costs of opioid abuse among a commercially insured population. Am J Manag Care. 2017;23(5):276\u201382.","journal-title":"Am J Manag Care."},{"issue":"S2","key":"402_CR22","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1080\/00325481.2016.1224633","volume":"128","author":"J Howard","year":"2016","unstructured":"Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, et al. The economic burden of opioid abuse and its drivers: evidence from a payer perspective. Postgrad Med. 2016;128(S2):42. \n                    https:\/\/doi.org\/10.1080\/00325481.2016.1224633\n                    \n                  .","journal-title":"Postgrad Med."},{"issue":"S2","key":"402_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/00325481.2016.1224633","volume":"128","author":"J Howard","year":"2016","unstructured":"Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, et al. The costs and cost drivers of opioid misuse by diagnosis: abuse, dependence, and overdose\/poisoning. Postgrad Med. 2016;128(S2):41. \n                    https:\/\/doi.org\/10.1080\/00325481.2016.1224633\n                    \n                  .","journal-title":"Postgrad Med."},{"issue":"3","key":"402_CR24","doi-asserted-by":"publisher","first-page":"E116","DOI":"10.1111\/papr.12147","volume":"14","author":"MK Pasquale","year":"2013","unstructured":"Pasquale MK, Joshi AV, Dufour R, Schaaf D, Mardekian J, Andrews GA, et al. Cost drivers of prescription opioid abuse in commercial and Medicare populations. Pain Pract Off J World Inst Pain. 2013;14(3):E116\u201325. \n                    https:\/\/doi.org\/10.1111\/papr.12147\n                    \n                  .","journal-title":"Pain Pract Off J World Inst Pain."},{"issue":"11","key":"402_CR25","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.18553\/jmcp.2017.17019","volume":"23","author":"LM Scarpati","year":"2017","unstructured":"Scarpati LM, Kirson NY, Jia ZB, Wen J, Howard J. Opioid abuse: A detailed examination of cost drivers over a 24-month follow-up period. J Manag Care Spec Pharm. 2017;23(11):1110\u20135. \n                    https:\/\/doi.org\/10.18553\/jmcp.2017.17019\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"4 Suppl","key":"402_CR26","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.18553\/jmcp.2016.22.4.S1","volume":"22","author":"J Howard","year":"2016","unstructured":"Howard J, Kirson N, Shei A, Cummings A, Birnbaum H. Drivers of excess costs associated with opioid abuse among commercially insured patients. J Manag Care Spec Pharm. 2016;22(4 Suppl):S58\u20139. \n                    https:\/\/doi.org\/10.18553\/jmcp.2016.22.4.S1\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"10","key":"402_CR27","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/MLR.0000000000000625","volume":"54","author":"CS Florence","year":"2016","unstructured":"Florence CS, Zhou C, Luo F, Xu L. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med Care. 2016;54(10):901\u20136. \n                    https:\/\/doi.org\/10.1097\/mlr.0000000000000625\n                    \n                  .","journal-title":"Med Care."},{"issue":"10","key":"402_CR28","doi-asserted-by":"publisher","first-page":"902","DOI":"10.18553\/jmcp.2015.21.10.902","volume":"21","author":"A Shei","year":"2015","unstructured":"Shei A, Rice JB, Kirson NY, Bodnar K, Enloe CJ, Birnbaum HG, et al. Characteristics of high-cost patients diagnosed with opioid abuse. J Manag Care Spec Pharm. 2015;21(10):902\u201312. \n                    https:\/\/doi.org\/10.18553\/jmcp.2015.21.10.902\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"8","key":"402_CR29","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3111\/13696998.2015.1036760","volume":"18","author":"CV Asche","year":"2015","unstructured":"Asche CV, Clay E, Kharitonova E, Zah V, Ruby J, Aballea S. Budgetary impact of the utilization of buprenorphine\/naloxone sublingual film and tablet for Medicaid in the United States. J Med Econ. 2015;18(8):600\u201311. \n                    https:\/\/doi.org\/10.3111\/13696998.2015.1036760\n                    \n                  .","journal-title":"J Med Econ."},{"issue":"10","key":"402_CR30","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/pme.12183","volume":"14","author":"TJ Inocencio","year":"2013","unstructured":"Inocencio TJ, Carroll NV, Read EJ, Holdford DA. The economic burden of opioid-related poisoning in the United States. Pain Med. 2013;14(10):1534\u201347. \n                    https:\/\/doi.org\/10.1111\/pme.12183\n                    \n                  .","journal-title":"Pain Med."},{"issue":"5","key":"402_CR31","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.jval.2017.05.005","volume":"20","author":"A Descoteaux","year":"2017","unstructured":"Descoteaux A, Borrelli E, Kogut S. A budget impact analysis of abuse deterrent opioid formulation. Value Health. 2017;20(5):A1\u2013383. \n                    https:\/\/doi.org\/10.1016\/S1098-3015(17)30183-3\n                    \n                  .","journal-title":"Value Health."},{"issue":"10-a Suppl","key":"402_CR32","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.18553\/jmcp.2017.23.10-a.s1","volume":"23","author":"J Carter","year":"2017","unstructured":"Carter J, Frost M, Sanjurjo V. Determining the economic impact of medication nonadherence in persons treated with depot-injectable or sublingual buprenorphine for opioid use disorder. J Manag Care Spec Pharm. 2017;23(10-a Suppl):S1\u201392. \n                    https:\/\/doi.org\/10.18553\/jmcp.2017.23.10-a.s1\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"3","key":"402_CR33","first-page":"77","volume":"14","author":"M Geitona","year":"2012","unstructured":"Geitona M, Carayanni V, Petratos P. Economic evaluation of opioid substitution treatment in Greece. Heroin Addict Relat Clin Probl. 2012;14(3):77\u201388.","journal-title":"Heroin Addict Relat Clin Probl."},{"issue":"11","key":"402_CR34","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/JOM.0000000000000865","volume":"58","author":"SS Johnston","year":"2016","unstructured":"Johnston SS, Alexander AH, Masters ET, Mardekian J, Semel D, Malangone-Monaco E, et al. Costs and work loss burden of diagnosed opioid abuse among employees on workers compensation or short-term disability. J Occup Environ Med. 2016;58(11):1087\u201397. \n                    https:\/\/doi.org\/10.1097\/jom.0000000000000865\n                    \n                  .","journal-title":"J Occup Environ Med."},{"key":"402_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.drugalcdep.2014.02.701","volume":"138","author":"BN Cochran","year":"2014","unstructured":"Cochran BN, Flentje A, Heck NC, Van Den Bos J, Perlman D, Torres J, et al. Factors predicting development of opioid use disorders among individuals who receive an initial opioid prescription: mathematical modeling using a database of commercially-insured individuals. Drug Alcohol Depend. 2014;138:202\u20138. \n                    https:\/\/doi.org\/10.1016\/j.drugalcdep.2014.02.701\n                    \n                  .","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"402_CR36","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1080\/08897077.2014.996697","volume":"36","author":"SL Calcaterra","year":"2015","unstructured":"Calcaterra SL, Keniston A, Blum J, Crume T, Binswanger IA. The association between stimulant, opioid, and multiple drug use on behavioral health care utilization in a safety-net health system. Subst Abuse. 2015;36(4):407\u201312. \n                    https:\/\/doi.org\/10.1080\/08897077.2014.996697\n                    \n                  .","journal-title":"Subst Abuse."},{"issue":"3","key":"402_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.5055\/jom.2013.0158","volume":"9","author":"CL Roland","year":"2013","unstructured":"Roland CL, Joshi AV, Mardekian J, Walden SC, Harnett J. Prevalence and cost of diagnosed opioid abuse in a privately insured population in the United States. J Opioid Manag. 2013;9(3):161\u201375. \n                    https:\/\/doi.org\/10.5055\/jom.2013.0158\n                    \n                  .","journal-title":"J Opioid Manag."},{"issue":"5","key":"402_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/papr.12097","volume":"14","author":"O Baser","year":"2014","unstructured":"Baser O, Xie L, Mardekian J, Schaaf D, Wang L, Joshi AV. Prevalence of diagnosed opioid abuse and its economic burden in the veterans health administration. Pain Pract Off J World Inst Pain. 2014;14(5):437\u201345. \n                    https:\/\/doi.org\/10.1111\/papr.12097\n                    \n                  .","journal-title":"Pain Pract Off J World Inst Pain."},{"issue":"5","key":"402_CR39","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1016\/j.jval.2017.05.005","volume":"20","author":"AM Patel","year":"2017","unstructured":"Patel AM, Wheeler DC, Rose SR, Nadpara PA, Pakyz AL, Carroll NV. Economic burden associated with pediatric opioid poisonings. Value Health. 2017;20(5):A1\u2013383. \n                    https:\/\/doi.org\/10.1016\/S1098-3015(17)30183-3\n                    \n                  .","journal-title":"Value Health."},{"issue":"3","key":"402_CR40","doi-asserted-by":"publisher","first-page":"A188","DOI":"10.1016\/j.jval.2016.03.1375","volume":"19","author":"B Brady","year":"2016","unstructured":"Brady B, Tkacz J, Nadipelli V, Volpicelli J, Ronquest N, Un H, et al. Relapse in opioid use disorder: implications for health care utilization and costs. Value Health. 2016;19(3):A188. \n                    https:\/\/doi.org\/10.1016\/j.jval.2016.03.1375\n                    \n                  .","journal-title":"Value Health."},{"issue":"4","key":"402_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jsat.2013.10.014","volume":"46","author":"J Tkacz","year":"2014","unstructured":"Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456\u201362. \n                    https:\/\/doi.org\/10.1016\/j.jsat.2013.10.014\n                    \n                  .","journal-title":"J Subst Abuse Treat."},{"issue":"3","key":"402_CR42","doi-asserted-by":"publisher","first-page":"A187","DOI":"10.1016\/j.jval.2016.03.1371","volume":"19","author":"J Tkacz","year":"2016","unstructured":"Tkacz J, Brady B, Nadipelli V, Volpicelli J, Ronquest N, Un H, et al. The association between buprenorphine medication-assisted treatment adherence and health care service utilization and costs. Value Health. 2016;19(3):A187. \n                    https:\/\/doi.org\/10.1016\/j.jval.2016.03.1371\n                    \n                  .","journal-title":"Value Health."},{"issue":"9","key":"402_CR43","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3111\/13696998.2014.925463","volume":"17","author":"E Clay","year":"2014","unstructured":"Clay E, Khemiri A, Zah V, Aballea S, Ruby J, Asche CV. Persistence and healthcare utilization associated with the use of buprenorphine\/naloxone film and tablet formulation therapy in adults with opioid dependence. J Med Econ. 2014;17(9):626\u201336. \n                    https:\/\/doi.org\/10.3111\/13696998.2014.925463\n                    \n                  .","journal-title":"J Med Econ."},{"issue":"5","key":"402_CR44","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3810\/pgm.2014.09.2805","volume":"126","author":"A Khemiri","year":"2014","unstructured":"Khemiri A, Kharitonova E, Zah V, Ruby J, Toumi M. Analysis of buprenorphine\/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims. Postgrad Med. 2014;126(5):113\u201320. \n                    https:\/\/doi.org\/10.3810\/pgm.2014.09.2805\n                    \n                  .","journal-title":"Postgrad Med."},{"issue":"10-a Suppl","key":"402_CR45","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.18553\/jmcp.2017.23.10-a.s1","volume":"23","author":"A Shah","year":"2017","unstructured":"Shah A, Atreja N, Duncan M, Tai K, Gore M. Health care utilization and costs associated with pharmacological therapy versus non-pharmacologic therapy for opioid dependence. J Manag Care Spec Pharm. 2017;23(10-a Suppl):S42. \n                    https:\/\/doi.org\/10.18553\/jmcp.2017.23.10-a.s1\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"10-a Suppl","key":"402_CR46","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.18553\/jmcp.2017.23.10-a.s1","volume":"23","author":"A Shah","year":"2017","unstructured":"Shah A, Duncan M, Atreja N, Sun X, Tai K, Gore M. Health care utilization and costs associated with opioid dependence treatments. J Manag Care Spec Pharm. 2017;23(10-a Suppl):S42\u20133. \n                    https:\/\/doi.org\/10.18553\/jmcp.2017.23.10-a.s1\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"5","key":"402_CR47","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/bcp.12446","volume":"78","author":"B Blanch","year":"2014","unstructured":"Blanch B, Pearson SA, Haber PS. An overview of the patterns of prescription opioid use, costs and related harms in Australia. Br J Clin Pharmacol. 2014;78(5):1159\u201366. \n                    https:\/\/doi.org\/10.1111\/bcp.12446\n                    \n                  .","journal-title":"Br J Clin Pharmacol."},{"key":"402_CR48","unstructured":"Weiss AJ, Elixhauser A, Barrett ML, Steiner CA, Bailey MK, O\u2019Malley L. Opioid-related inpatient stays and emergency department visits by state, 2009\u20132014. Statistical brief #219. December 2016. Agency for healthcare research and quality. \n                    https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb219-Opioid-Hospital-Stays-ED-Visits-by-State.pdf\n                    \n                  . Accessed 23 Jan 2018."},{"key":"402_CR49","unstructured":"Commonwealth of Massachusetts Health Policy Commission. Opioid use disorder in Massachusetts: an analysis of its impact on the health care system, availability of pharmacologic treatment, and recommendations for payment and care delivery reform. Massachusetts Heath Policy Commission; 2016."},{"issue":"4 Suppl","key":"402_CR50","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.18553\/jmcp.2016.22.4.S1","volume":"22","author":"P Holly","year":"2016","unstructured":"Holly P, Kirson N, Shei A, Howard J, Cummings A, Birnbaum H. Understanding drivers of excess costs among continuous users of extended-release\/long-acting opioids diagnosed with opioid abuse, dependence, or poisoning. J Manag Care Spec Pharm. 2016;22(4 Suppl):S59. \n                    https:\/\/doi.org\/10.18553\/jmcp.2016.22.4.S1\n                    \n                  .","journal-title":"J Manag Care Spec Pharm."},{"issue":"3","key":"402_CR51","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1016\/j.jval.2016.03.018","volume":"19","author":"ET Masters","year":"2016","unstructured":"Masters ET, Mardekian J, Ramaprasan A, Saunders K, Gross DE, Palmer RE, et al. Natural language processing-identified problem opioid use and its associated health care costs. Value Health. 2016;19(3):A4. \n                    https:\/\/doi.org\/10.1016\/j.jval.2016.03.018\n                    \n                  .","journal-title":"Value Health."},{"key":"402_CR52","unstructured":"Centers for Medicare and Medicaid Services (CMS). Centers for Medicare and Medicaid Services (CMS) opioid misuse strategy 2016. 2017. \n                    https:\/\/www.cms.gov\/Outreach-and-Education\/Outreach\/Partnerships\/Downloads\/CMS-Opioid-Misuse-Strategy-2016.pdf\n                    \n                  . Accessed 14 June 2018."},{"issue":"3","key":"402_CR53","doi-asserted-by":"publisher","first-page":"E106","DOI":"10.1111\/papr.12148","volume":"14","author":"R Dufour","year":"2014","unstructured":"Dufour R, Joshi AV, Pasquale MK, Schaaf D, Mardekian J, Andrews GA, et al. The prevalence of diagnosed opioid abuse in commercial and Medicare managed care populations. Pain Pract Of J World Inst Pain. 2014;14(3):E106\u201315. \n                    https:\/\/doi.org\/10.1111\/papr.12148\n                    \n                  .","journal-title":"Pain Pract Of J World Inst Pain."},{"issue":"8","key":"402_CR54","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1526-4637.2006.00200.x","volume":"8","author":"MJ Edlund","year":"2007","unstructured":"Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB. Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med. 2007;8(8):647\u201356. \n                    https:\/\/doi.org\/10.1111\/j.1526-4637.2006.00200.x\n                    \n                  .","journal-title":"Pain Med."},{"key":"402_CR55","unstructured":"Heslin KC, Elixhauser A, Steiner CA. Hospitalizations involving mental and substance use disorders among adults, 2012. HCUP Statistical Brief #191. Agency for Healthcare Research and Quality, Rockville, MD. 2015. \n                    https:\/\/www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb191-Hospitalization-Mental-Substance-Use-Disorders-2012.pdf\n                    \n                  . Accessed 14 June 2018."},{"key":"402_CR56","unstructured":"The Council of Economic Advisers. The underestimated cost of the opioid crisis. 2017. \n                    https:\/\/www.whitehouse.gov\/sites\/whitehouse.gov\/files\/images\/The%20Underestimated%20Cost%20of%20the%20Opioid%20Crisis.pdf\n                    \n                  . Accessed 14 June 2018."},{"key":"402_CR57","unstructured":"Institute for Clinical and Economic Review (ICER). Final evidence report\u2014Abuse-deterrent formulations of opioids: Effectiveness and value. 2017. \n                    https:\/\/icer-review.org\/wp-content\/uploads\/2016\/08\/NECEPAC_ADF_Evidence_Report_062817.pdf\n                    \n                  . Accessed 14 June 2018."},{"key":"402_CR58","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jsat.2015.05.001","volume":"57","author":"RE Clark","year":"2015","unstructured":"Clark RE, Baxter JD, Aweh G, O\u2019Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75\u201380. \n                    https:\/\/doi.org\/10.1016\/j.jsat.2015.05.001\n                    \n                  .","journal-title":"J Subst Abuse Treat."},{"key":"402_CR59","unstructured":"United Nations Office on Drugs and Crime (UNODC). World drug report: global overview of drug demand and supply. 2017. \n                    https:\/\/www.unodc.org\/wdr2017\/field\/Booklet_2_HEALTH.pdf\n                    \n                  . Accessed 19 Jan 2018."},{"issue":"5","key":"402_CR60","doi-asserted-by":"publisher","first-page":"A371","DOI":"10.1016\/S1098-3015(17)30183-3","volume":"20","author":"BS Electricwala","year":"2017","unstructured":"Electricwala BS, Carroll NV, Nadpara P, Cannon E, Wander C. Prevalence, incremental cost and resource utilization associated with opioid overdose in the United States. Value Health. 2017;20(5):A371\u20132. \n                    https:\/\/doi.org\/10.1016\/S1098-3015(17)30183-3\n                    \n                  .","journal-title":"Value Health."},{"issue":"4","key":"402_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.3111\/13696998.2014.897628","volume":"17","author":"LF Rossiter","year":"2014","unstructured":"Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17(4):279\u201387. \n                    https:\/\/doi.org\/10.3111\/13696998.2014.897628\n                    \n                  .","journal-title":"J Med Econ."}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40258-018-0402-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-018-0402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T21:13:40Z","timestamp":1589922820000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40258-018-0402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,20]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1007\/s40258-018-0402-x","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,20]]},"assertion":[{"value":"20 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was funded by Purdue Pharma L.P. NYK, CP, MR, LMS, and NS are employees of Analysis Group, Inc., a company that received funding from Purdue Pharma L.P. to conduct this study. JGE is a full-time employee of Purdue Pharma L.P.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}}]}}